香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED 獨立非執行董事辭任 瑞慈醫療服務控股有限公司（「本公司」，連同其附屬公司為「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，王勇博士（「王博士」）為投入更多時間專注於彼 之其他商業事務，已辭任獨立非執行董事及本公司審核委員會（「審核委員會」） 成員，自2025年12月29日起生效。 王博士已確認，彼與董事會及本公司並無意見分歧，亦無其他有關彼辭任的事 宜須提請香港聯合交易所有限公司及本公司股東垂注。 （於開曼群島註冊成立的有限公司） （股份代號：1526） (1) 獨立非執行董事辭任； (2) 委任獨立非執行董事；及 (3) 董事委員會組成變動 董事會謹此衷心感謝王博士於擔任獨立非執行董事期間對本公司作出的寶貴 貢獻。 – 1 – 委任獨立非執行董事 董事會欣然宣佈已委任田文果先生（「田先生」）擔任本公司獨立非執行董事以 填補臨時空 ...

Group 1: 52-Week Highs - A total of 36 stocks reached their 52-week highs as of December 18, with Guangjun Group Holdings (08573) leading at a high rate of 112.12% [1] - Huamei Lele (08429) and Gaoke Bridge (09963) followed with high rates of 53.70% and 32.86% respectively [1] - The closing prices and highest prices for the top three stocks were as follows: Guangjun Group Holdings at 0.077 and 0.140, Huamei Lele at 0.062 and 0.083, and Gaoke Bridge at 0.780 and 0.930 [1] Group 2: 52-Week Lows - The 52-week low rankings showed that Ruici Medical (01526) had the highest decline rate at -17.44% [2] - Yili Holdings (00076) and Cao Cao Chuxing (02643) followed with declines of -17.00% and -11.03% respectively [2] - The closing prices and lowest prices for the top three stocks were: Ruici Medical at 0.870 and 0.710, Yili Holdings at 0.185 and 0.166, and Cao Cao Chuxing at 28.960 and 28.880 [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 本月底法定/註冊股本總額： USD 1,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結 ...

在传统超声领域，双方还将携手打造非公医疗领域首个"人工智能超声应用联合创新中心"。 从行业情况来看，当前的传统超声领域，正处在一个技术融合与市场格局剧变的时期。"人工智能超声 应用联合创新中心"旨在攻克超声检查长期面临的操作者依赖性强、效率低等行业难题。基于此，该中 心将构建一个从"数据"到"临床"的完整创新闭环：瑞慈医疗集团将开放其覆盖多地域、多人群的海量超 声影像数据与资深医师的专家经验；联影集团则注入其在医学影像AI领域深厚的算法积累与工程化能 力，共同推动超声检查的标准化、智能化与普惠化。 双方认为，此次瑞慈医疗集团与联影集团的战略携手，超越了单一的影像设备合作，未来将在人工智 能、健康管理中心运营、治疗设备多领域全面深度交流，是一次从设备应用到临床服务模式的深度共 创；并且，双方将以此次合作为新起点，持续探索科技与医疗融合的更多可能性，共同致力于医疗质量 的提升、运营效率的突破与患者体验的革新。 （文章来源：证券时报网） "2025年是医疗大模型元年，AI新技术正快速重塑整个医疗行业，此次与联影集团的战略协同，依托联 影集团全线高端医疗装备与诊疗一体化AI，深度赋能瑞慈医疗集团未来布局与智能化升级。 ...

Core Viewpoint - 瑞慈医疗 has made a significant investment by purchasing a luxury villa in Shanghai for approximately 199 million RMB, which is a strategic move to enhance its asset portfolio amidst challenges in its core medical business [1][4]. Group 1: Investment Details - The property acquired is a villa located at Longqi Road, covering an area of approximately 570.06 square meters, with a transaction price of about 34.9 million RMB per square meter, surpassing the average recorded price of 29.8 million RMB per square meter [3][12]. - 瑞慈医疗 has paid an initial deposit of 30 million RMB, with the remaining 169 million RMB due by November 30 [3]. - This investment represents over 13.67% of 瑞慈医疗's market capitalization, which is approximately 1.56 billion RMB [4]. Group 2: Financial Context - As of June 30, 2025, 瑞慈医疗 reported cash and cash equivalents of about 1.03 billion RMB, indicating that the villa purchase significantly impacts its cash reserves [3]. - The company’s asset-liability ratio stands at 46.2%, slightly down from 46.4% at the end of 2024, while the scale of mortgaged assets has nearly doubled within six months [8][9]. - The acquisition is seen as a long-term investment opportunity, potentially providing reasonable returns due to the property's location in a core commercial area of Shanghai [4]. Group 3: Market Position and Challenges - 瑞慈医疗 is currently experiencing a revenue decline, with a 7% year-on-year decrease in revenue to 1.145 billion RMB in the first half of 2025, attributed to external competitive pressures [8]. - The company’s net profit for the same period fell by 34.18% to 55.94 million RMB, despite an increase in gross margin from 32.2% to 35.6% [8]. - The decision to invest in prime real estate reflects a strategy to diversify and maintain cash flow amid pressures from medical insurance cost control and market competition [9].

Core Insights - The recent purchase of luxury properties by companies like 瑞慈医疗 and 嘉里建设 highlights the ongoing strength of the high-end real estate market in Shanghai, despite a broader industry downturn [2][6][8] - 瑞慈医疗's acquisition of a villa for approximately 1.99 billion yuan reflects a strategic long-term investment in a prime location, indicating confidence in future capital appreciation [3][4] - 嘉里建设's purchase of a property for 1.17 billion yuan and the subsequent strong sales performance of its 金陵华庭 project demonstrate robust demand for luxury housing in Shanghai [6][7] Company Actions - 瑞慈医疗's indirect subsidiary, 上海瑞慈瑞铂门诊部有限公司, purchased a residential unit in 云锦东方, with a total area of about 570.06 square meters at a price of 34.9 million yuan per square meter [3][4] - 嘉里建设's chairman, 郭孔华, acquired a 449 square meter unit in 金陵华庭 for 1.17 billion yuan, with expectations of generating approximately 23 million yuan in profit from the transaction [6][7] Market Trends - The luxury real estate market in Shanghai is experiencing significant growth, with high-end properties priced over 50 million yuan seeing a 27% increase in transactions year-on-year [2][8] - In the first three quarters of 2025, luxury properties accounted for nearly 80% of total transactions in 11 major cities across China, indicating a strong preference for high-value assets [8] - The recent sales performance of 金陵华庭, which sold out quickly at high prices, reflects a strong demand for luxury housing driven by affluent buyers seeking core assets [7][8]

Core Viewpoint - 瑞慈医疗 has made a strategic investment by purchasing a luxury residential unit in Shanghai, viewing it as a long-term investment opportunity in a prime location with significant growth potential [1][2]. Company Summary - 瑞慈医疗's subsidiary, Shanghai Ruici Ruibo Outpatient Department Co., Ltd., acquired a residential unit for approximately 199 million yuan, with a total area of about 570.06 square meters [1]. - The company has paid a deposit of 30 million yuan, with the remaining 169 million yuan to be settled by November 30 [1]. - The purchased property is part of the Yun Jin Dong Fang project, which has seen high demand due to its luxury status and celebrity residents [1]. Industry Summary - The Shanghai real estate market has experienced a contraction in supply, with new housing supply decreasing by approximately 19% year-on-year to 1.3156 million square meters in the third quarter [4]. - Despite the reduced supply, the overall average price of new homes in Shanghai has increased by about 8.5% year-on-year, driven by the entry of luxury properties and relaxed price controls [4]. - The market is shifting towards a more normalized sales environment, with a recovery in the absorption rate to around 80% in core areas, indicating a potential upward trend in property prices due to various factors such as industrial development and population influx [5].

Group 1 - The core viewpoint of the news is that Ruici Medical has made a strategic investment by purchasing a luxury residential unit in Shanghai, indicating confidence in the long-term capital appreciation potential of the property market in the city [1][2][4] - Ruici Medical's subsidiary, Shanghai Ruici Ruibo Clinic, acquired a residential unit for approximately 199 million yuan, with a total area of about 570.06 square meters, reflecting a price of 349,000 yuan per square meter [1][4] - The property is located in the prestigious Yunjin Dongfang project, which has seen significant demand due to its high-profile celebrity residents and the overall market trend of rising prices despite a contraction in new housing supply [1][4][5] Group 2 - The company views this acquisition as a favorable medium to long-term investment, benefiting from Shanghai's status as a major economic and financial hub with substantial growth potential [2][4] - The Shanghai real estate market has experienced a decrease in new housing supply by approximately 19% year-on-year, yet the overall average price has increased by about 8.5% due to the concentration of luxury properties entering the market [4][5] - The market is shifting towards a more normalized sales environment, with core areas seeing a recovery in sales rates to around 80%, indicating a potential upward trend in property prices driven by new luxury developments [5]

Core Viewpoint - 瑞慈医疗 has made a strategic investment by purchasing a luxury residential unit in Shanghai, viewing it as a long-term investment opportunity in a prime location with significant growth potential [2][3]. Company Summary - 瑞慈医疗's indirect wholly-owned subsidiary, Shanghai Ruici Ruibo Clinic Co., Ltd., has acquired a residential unit for approximately 199 million yuan, with a total area of about 570.06 square meters [1]. - The company has paid a deposit of 30 million yuan, with the remaining 169 million yuan to be settled by November 30, funded through internal resources [1]. - The purchased property is part of the high-end residential project, 云锦东方, which has seen increased demand due to its location and celebrity residents [1]. Industry Summary - The Shanghai real estate market has experienced a contraction in new housing supply, with a year-on-year decrease of about 19% in supply area during the third quarter [3]. - Despite the reduced supply, the overall average price of new homes in Shanghai has increased by approximately 8.5% year-on-year, driven by the entry of luxury properties and relaxed price controls [3]. - The market is shifting towards a more normalized sales environment, with core areas benefiting from resource aggregation and high-quality products, leading to a recovery in sales rates to about 80% [3].

Core Viewpoint - 瑞慈医疗 announced the purchase of a residential property in Shanghai for a total consideration of RMB 200 million, indicating strategic expansion in the real estate sector [1] Group 1: Transaction Details - The buyer, Shanghai Ruici Ruibo Outpatient Department Co., Ltd., is a wholly-owned subsidiary of 瑞慈医疗 [1] - The seller, Shanghai Eastern Airlines Real Estate Co., Ltd., is an independent third party [1] - The property is located at Longqi Road, Shanghai, with a total construction area of approximately 570.06 square meters [1]